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New Insulin Preparations: 
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By: Dana Brackney
Abstract
Concentrated insulins have been especially problematic high alert medications. On February 25, 
2015 Federal Drug Administration (FDA) approval made available insulin glargine, Toujeo 
U-300 (300 units/ml) in a SoloSTAR pen. On May 27, 2015 the FDA approved insulin lispro, 
Humalog U-200 (200 units/ml) KwikPen. Increased incidence of insulin resistant type 2 
diabetes has escalated the need for concentrated insulin. This paper discusses each insulin, 
appropriate patient selection, benefits of the new insulins for people with diabetes and 
providers, and suggestions for prevention of potential off-label use of insulin pens. Counseling 
and assessment are essential to avoid unintended harm.
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New
Bene Insulin Preparations: Potential 
fits and Risk Assessmentsnsulin in any form is a high-alert medication. Two
new products address safety concerns related toIinsulin pharmacology and administration. On
February 25, 2015, the Federal Drug Administration
approved insulin glargine (Toujeo U-300 [300 U/mL],
Sanofi-Aventis, Bridgewater, NJ) delivered subcuta-
neously with a SoloSTAR insulin pen.1 Then, on May
27, 2015, the Food and Drug Administration approved
insulin lispro (Humalog U-200 [200 U/mL]
KwikPen, Eli Lilly and Company, Indianapolis, IN).2
Factors motivating the development of these products
include 1) the growing number of people using more
than 200 units of insulin per day because of insulin-
resistant type 2 diabetes (T2DM) and 2) safety issues
associated with concentrated insulin dosing and
administration. In response, manufacturers released
these insulins in pen form only1,3 (Toujeo and
Humalog U-200) and modified the insulin
pharmacokinetics and pharmacodynamics (Toujeo).1
The increased incidence of insulin-resistant T2DM
has created a need for concentrated, long-acting, in-
sulin with a stable action over time.4,5 Insulin with
steady bioavailability over time is characterized as
having a flat time action curve. Insulin without a
peak action (flat time action curve) is desired clinically
in order to meet the body’s ongoing physiologicneed for basal (background) insulin while preventing
hypoglycemia. In contrast, a steep time action curve
is appropriate for bolus (meal time) insulin. Clinically,
this peak of insulin action is beneficial, paralleling the
increased glycemic load of a meal.
Particularly during care transitions and/or in hos-
pital settings, patients using concentrated U-500 insulin
were at increased risk for medication errors.6,7 Reports
of insulin administration errors related to the use of
U-500 insulin in hospital settings are well documented.5-8
Errors have multiple contributing factors. One factor is
that U-500 insulin syringes are not available.5,6 Instead,
the person administering the insulin must convert
the concentrated insulin dose for administration in a
U-100 or tuberculin syringe. U-500 dosage errors
occur when calculating this volume-based dose
without an equivalent unit-based syringe.6,7 Insulin
dosing and administration errors created a need for
a safer means of administering concentrated insulin.
Adults with type 1 diabetes (T1DM) or T2DM and
providers benefit from the approval of both new
concentrated formulations of insulin in multiple ways.
INSULIN GLARGINE: TOUJEO U-300
Toujeo U-300 (glargine U-300) has been approved
for use in adults with T1DM and T2DM.1 Insulin
glargine substitutes Gly for 21A-Asn in its amino
acid sequence,9 creating an acid soluble solution
that precipitates at physiologic pH forming a depot
that slowly releases insulin glargine.10,11 Glargine
U-300 has a flatter and longer pharmacokinetic and
pharmacodynamics profile than glargine U-100.9,12
Clinically, these characteristics prevent basal insulin
gaps and hypoglycemia. Glargine U-300 users
experienced fewer hypoglycemic episodes (14%
reduction overall and 31% reduction in nocturnal
hypoglycemia)13,14 and less weight gain.9 Adults with
T1DM using glargine U-300 had fewer glycemic
fluctuations as measured with continuous glucose
monitoring than those using glargine U-100.15 This
finding demonstrates benefit for all basal insulin users.
Once daily subcutaneous injections of glargine
U-300 may take up to 5 days to reach a steady state.1
This longer time to a steady state is one reason Toujeo
is not indicated for use in diabetic ketoacidosis.1
Currently, the cash price of Toujeo (glargine U-300) is
approximately $0.27 per unit.16 This cost is about
$0.53 more per 1,000 units than glargine U-100.16,17
Coupons and copay discounts are available and were
not considered in this calculation. Price information
varies widely and is available at sites such as www
.drugs.com. Full prescribing information is available at
https://www.toujeopro.com/dosing-and-administration.
INSULIN LISPRO: HUMALOG U-200
Humalog U-200 (lispro U-200) is bioequivalent to
Humalog U-100 (lispro U-100) and approved for
adults with T1DM and T2DM.3 The pharmacokinetics
and pharmacodynamics of Humalog U-200 are
unchanged from those of Humalog U-100.3 Both
concentrations are administered 15 minutes before or
immediately after a meal. A patient education sheet
is available at http://pi.lilly.com/us/humalog-u200
-ppi.pdf. Although Humalog U-100 is available in
vial or KwikPen, the Humalog U-200 formulation
is available only in the KwikPen.3 The cash price of
the Humalog U-100 KwikPen is around $0.31 per
unit.18 The cash price of Humalog U-200 with a
discount coupon ranges from $0.26 per unit to $0.37
per unit.19 The Humalog U-200 KwikPen averaged
around $9.95 more for 1,000 units than the Humalog
U-100 KwikPen. However, prices vary widely,
and erroneous online pharmacy information wascommon (eg, Humalog U-200 KwikPen is packaged
with 2 pens not 519).
INSULIN PEN
Thin pen needles create challenges for high-volume
insulin administration by increasing the time it takes
to deliver the insulin dose.20 Removing the pen too
soon during insulin administration reduces the insulin
delivered by the pen.20 A more concentrated (lower
volume) insulin delivered by the pen decreases insulin
administration time and may decrease the incidence of
insulin underdelivery caused by early needle removal.
One injection with the SoloSTAR pen delivers up to
80 units of glargine U-300. The glargine U-300 dose is
equivalent to a glargine U-100 dose with a third of the
insulin volume.9TheKwikPendelivers up to 60units of
lisproU-200 with half the insulin volume of the U-100
pen.3 Both pens are calibrated by 1-unit increments.1-3
DOSING
Concentrated insulin (eg, U-500) has been available
since the 1950s.8 Understanding insulin concentrations
is key when prescribing and counseling patients.
U-100, U-200, and U-300 describe the number of
units in 1 mL insulin. It is a ratio used to convey
concentration. For example, 1 mL U-200 insulin
contains 200 units, whereas 1 mL U-300 insulin
contains 300 units. The subcutaneous delivery of
U-200 and U-300 insulins with an insulin pen is
an innovation designed to prevent dosing errors.
Manufacturers1,3 have engineered the pens’
mechanism to control the volume that each unit
marking on the pen delivers to the person with
diabetes. Fifty units of a U-100 insulin equals 0.5 mL
insulin. However, 50 units of a U-200 insulin
administered with a pen delivers half that volume
(0.25 mL) of insulin, with a similar efficacy to the
50-unit U-100 insulin dosage. Previously prescribing
a concentrated insulin required translation of the dose
for delivery with a U-100 or tuberculin syringe. For
current U-100 insulin users, the prescriber simply
orders the same number of U-200 or U-300 units,
and the pen mechanism converts the volume.
A basal insulin, glargine U-300, is dosed subcuta-
neously at a consistent time once daily. First calculate
the total daily insulin dose for an insulin-naive client
as 0.2 to 0.4 units of insulin/kg. Then, prescribe one
half to one third of this calculated total daily insulin
dose to initiate the glargine U-300.1 This initial
glargine U-300 basal dose is titrated 1 to 2 units every
3 to 4 days until the fasting glycemic goal is
achieved.1 Glargine U-300 may take 5 days to reach
a steady state.1 Therefore, dosage adjustments should
not be more frequent than every 3 to 4 days. The
remainder of the total daily insulin requirements are
met with a rapid-acting mealtime bolus insulin. In
the basal insulineusing adult, initiate glargine U-300
with the same basal insulin units as the U-100 basal.
People required slightly more glargine U-300 units
than those using glargine U-100 to reach their blood
glucose goals.1 Each glargine Toujeo U-300 SoloSTAR
pen contains 450 units and expires after 28 days from
the first use.1 Individuals requiring as little as 15 units
a day would consume 1 pen before expiration. See
full Toujeo prescribing information at https://www
.toujeopro.com/dosing-and-administration.
Lispro U-200 is a rapid-acting insulin and is
administered subcutaneously 15 minutes before or
immediately after a meal.3 Peak action is 30 to 90
minutes after dosing.3 Dosing is based on carbohydrate
and meal composition with considerations for activity
and current blood glucose readings. Dosages are
commonly from 0.1 to 0.4 unit/kg.3 Lispro U-200
is not approved for use in an insulin pump or
intravenously.3 Each Humalog U-200 KwikPen
contains 600 units of insulin that are to be consumed
within 28 days of the first use.3 Individuals using
at least 20 units a day would empty the pen’s contents
before the 28-day expiration. See full prescribing
information at http://www.humalog.com/diabetes
-information-for-healthcare-providers.aspx?
Adverse Effects
Hypoglycemia is a risk of insulin use. Individuals with
diabetes need to be aware of signs/symptoms of
hypoglycemia and how to treat it. Lipodystrophy, a
loss of fat appearing as a dimple in the skin at insulin
injections sites, is a risk for insulin users and may be
avoided with careful injection site rotation.
BENEFITS
Benefits for People With Diabetes
The use of more concentrated insulin benefits adults
with type 2 diabetes who are using larger doses ofU-100 insulins.5 Larger dosages are described as > 200
units per day or  2 units of insulin per kilogram
of body weight daily.5 Often, people with insulin
resistance must inject basal insulin in 2 sites to receive
a single dose of insulin because of the high volume of
their insulin dosage and the limits of the pen. Now,
with concentrated insulin, people do not need to
divide their dose between 2 injections sites.21 Also,
the tendency for a person with diabetes to administer
less than a full dose is very real when the insulin
dosage exceeds the number of units that a pen is
capable of administering or when the dose takes
longer to administer. Finally, in both T1DM and
T2DM, the potential for steady insulin absorption
because of changes in the pharmacokinetics and
pharmacodynamics of lispro U-300 may reduce the
incidence of hypoglycemia.9
Provider Benefits
The pen mechanism removes the need for mathemat-
ical conversion of dosages when changing to a more
concentrated rapid (lispro U-200) or long-acting
(glargine U-300) insulin.20 The insulin pen converts
the U-200 or U-300 dose to the correct volume.1,3
Previously, misunderstandings about the form, type,
and dose of insulin during transitions in care and in
hospital settings resulted in medication errors.5,6 Also,
the administration of concentrated insulin in care
settings without a calibrated syringe increased the risk
for medication errors.5,6 Communication of insulin
dosage in standard U-100 units prevents provider
misunderstandings about the concentration of
insulin and alleviates confusion over how to correctly
measure and administer the insulin dose. These
insulins are only available in an insulin pen, which
lessens the potential for dose-related prescribing and
administration errors.
CLIENT CONTEXT
Many people starting on concentrated insulin have
had a lot of experience with insulin. Potentially, they
have also picked up some off-label habits. Some
people have proudly used the term “MacGyvering”
to describe these off-label improvisations.22,23
Bloggers and others describe using a syringe to
withdraw insulin from a pen and then using the
insulin in a pump or administering it with a
syringe.23,24 There are several reasons behind this
behavior. Some people do not have access to enough
pen needles to meet their needs or they do not want
to waste the partial dose of insulin remaining in
the pen. Family members with diabetes often share
insulin. Consider this case example; grandma has
insulin-resistant T2DM and uses U-500 insulin. At
times, her 26-year-old grandson with T1DM is
unable to obtain enough insulin to cover his needs
because of high insurance copays. Occasionally, he
borrows grandma’s insulin to fill the gap.
Combining these two off-label behaviors
(removing insulin from a pen into a syringe and
sharing insulin) can be dangerous for the person who
does not understand the differences between insulin
concentrations. Not accounting for the concentration
by transferring the insulin out of its pen into another
delivery device could result in severe hypoglycemia.
Counseling Conversations
When prescribing to or working with people using a
U-200 and/or U-300 insulin pen, it is important to
assess their understanding of the insulin they have
been prescribed and to assess their potential for risky
behavior related to off-label use of diabetes supplies.
Both of these new insulins should not be combined
in a syringe with other insulins because of the volume
dosing mechanism of the pen.1,3 Also, insulin pens
should never be shared between people even if the
needle is changed.25 The following should be done:
1. Assess the individual for the risk of insulin
sharing by asking, “How likely are you to share
or loan your insulin?” Do not ask a yes or
no question to get the most robust answer. In
families and individuals with known sharing or
any potential to share, consider providing more
education, asking them to sign a “contract”
stating they will not share. If the potential for
shared use exists, consider not providing the
new concentrated insulin as a precaution against
severe hypoglycemia.
2. Assess the individual for his or her potential to
use an insulin syringe to withdraw insulin from
the pen. Ask, “How often do you have diffi-
culty getting pen needles?” Again, asking with
the assumption that it may be difficult is a more
robust means of getting to the truth.3. Consider working with insurance companies
and pen needle suppliers to obtain enough pen
needles to prevent the temptation for extraction
of insulin from a pen with a syringe. If possible
remove syringes from the home environment.
Ask, “Do you or anyone in your family have
insulin syringes?”
4. Discuss the importance of only using the
pen and needles for the person for whom it
is prescribed. Consider calling it “personal
insulin.”
5. Emphasize that because of its concentration it
could be dangerous if given to someone for
whom it is not prescribed. Consider using
stickers on the pen cartridge to emphasize “no
sharing/withdrawing.”
Prescribing concentrated insulin is made safer
because of the availability of these insulins in pen
form only. The pen delivers a unit of U-200 or
U-300 insulin clinically equivalent to the action of
a unit of U-100 insulin.3,26 Previously, only U-100
syringes or tuberculin syringes were available for
concentrated insulin administration. This required
conversion of the concentrated insulin from units
into volume. Each U-200 and U-300 pen contains
more insulin units than its U-100 counterparts.
Fewer pens per month are necessary compared with
the number of U-100 pens per month. Currently,
the cash price of the new insulin pens are nearly
equivalent to their U-100 counterparts. Both insulins
have the potential to be an excellent tool for diabetes
management in the insulin-resistant person with
diabetes. Others with diabetes can also benefit from
the steady availability of glargine U-300 and/or the
convenience of a pen that contains a month’s supply
of insulin. The nurse practitioner who understands
potential risks in the everyday management of
diabetes is essential for the safe introduction of these
new insulin preparations.
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